RU-486: Demonstrating a Low Standard for Women's Health? : Hearing Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, Second Session, May 17, 2006, Volume 4 |
Other editions - View all
Common terms and phrases
abortifacient Acting Director Adverse Event Reports advisory committee agency approvable letter associated Barr Pharmaceuticals bleeding CDAD CDER clinical trials Clinton Clostridium sordellii Commissioner CTCAE Danco deaths decision difficile Director of CDER Drug Administration Drug Evaluation Drug Risk Assess ectopic pregnancy emergency contraception FDA officials FDA's Food and Drug gestational age Grade hemorrhage infra Appendix interfering with ADL issues labeling Life-threatening maternal medical abortion methotrexate Mifeprex mifepristone mifepristone abortions mifepristone and misoprostol misoprostol NAVIGATION NOTE Office of Drug Office of Postmarketing oral OTC switch application patients pediatric percent physicians Plan B OTC Population Council Postmarketing Drug Risk prescription public health Publish Date restrictions review staff Roussel Uclaf safe and effective safety sepsis sordellii infection SOUDER sponsor Subpart H surgical abortion surveillance Symptomatic syndrome termination toxic shock syndrome toxin transfusion treatment United vaginal women women's health younger adolescents